Methods of producing T memory stem cell populations

US11111478B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Luca Gattinoni · Washington, US
• Enrico Lugli · Bethesda, US
• Mario Roederer · Bethesda, US
• Nicholas P. Restifo · Chevy Chase Section Five, US

Key dates

• Filing date: May 13, 2019
• Grant date: Sep 7, 2021
• Expiry date: Nov 14, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2501/727
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating naïve T cells from a mammal, wherein the mammal is not a mouse; b) activating the naïve T cells and expanding the numbers of naïve T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO−, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.